Literature DB >> 7891304

On the absorption of alendronate in rats.

J H Lin1, I W Chen, F A deLuna.   

Abstract

Alendronate is an antiosteolytic agent under investigation for the treatment of a number of bone disorders. Since the compound is a zwitterion with five pKa values and is completely ionized in the intestine at the physiological pH, absorption is poor; less than 1% of an oral dose is available systemically in rats. In the present studies, absorption was found to be predominantly in the upper part of the small intestine. Administration of buffered solutions of alendronate (pH 2-11) did not improve absorption. Whereas food markedly impaired the absorption of alendronate, EDTA enhanced absorption in a dose-dependent manner. Pretreatment of rats with ulcerogenic agents, mepirizole, acetylsalicylic acid, or indomethacin, resulted in a 3-7-fold increase in the oral absorption of alendronate. The absorption of phenol red, added as an indicator of intestinal tissue damage, was also increased in rats with experimental peptic ulcers. The enhanced absorption of alendronate observed in rats with experimental peptic ulcers was attributed to the alteration of the integrity of the intestinal membrane.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7891304     DOI: 10.1002/jps.2600831218

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.

Authors:  H Cohen; V Solomon; I S Alferiev; E Breuer; A Ornoy; N Patlas; N Eidelman; G Hägele; G Golomb
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

2.  The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats.

Authors:  I Ballester; A Daddaoua; R López-Posadas; A Nieto; M D Suárez; A Zarzuelo; O Martínez-Augustin; F Sánchez de Medina
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

3.  Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women.

Authors:  W-Y Chiu; C-J Lin; W-S Yang; K-S Tsai; J-Y Reginster
Journal:  Osteoporos Int       Date:  2019-10-23       Impact factor: 4.507

4.  Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.

Authors:  H Cohen; I S Alferiev; J Mönkkönen; M J Seibel; T Pinto; A Ezra; V Solomon; D Stepensky; H Sagi; A Ornoy; N Patlas; G Hägele; A Hoffman; E Breuer; G Golomb
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

Review 5.  Pharmacokinetics of alendronate.

Authors:  A G Porras; S D Holland; B J Gertz
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

6.  Risedronate gastrointestinal absorption is independent of site and rate of administration.

Authors:  D Y Mitchell; R A Eusebio; L E Dunlap; K A Pallone; J D Nesbitt; D A Russell; M E Clay; P J Bekker
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

7.  Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.

Authors:  Jun Iwamoto; Mitsuyoshi Uzawa; Yoshihiro Sato; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  J Bone Miner Metab       Date:  2009-08-19       Impact factor: 2.626

8.  Core decompression and alendronate treatment of the osteonecrotic rat femoral head: computer-assisted analysis.

Authors:  Eli Peled; Jacob Bejar; Michal Barak; Eyal Orion; Doron Norman
Journal:  Int J Exp Pathol       Date:  2013-04-18       Impact factor: 1.925

9.  Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications.

Authors:  Xuetao Shi; Yingjun Wang; Li Ren; Yihong Gong; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-01       Impact factor: 4.200

10.  Upper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutition.

Authors:  Claudia Gómez Acotto; Carlos Antonelli; Damien Flynn; Dennis McDaid; Emilio J A Roldán
Journal:  Calcif Tissue Int       Date:  2012-08-26       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.